BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024
Language flag

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

PHI_progress-1024x576-1

BioStock: PHI´s CEO comments on latest advancements

BioStock reached out to PHI´s CEO, Patrik Eschricht, to learn more about the visions moving forward.
KT-seminar-The_Promise_of_Regenerqtion_Medicine_and_AI-Fb_bannernew

CERN seminar: The Promise of Regenerative Medicine and AI

During this seminar, Peter Egelberg, Founder of PHI, will present the work carried out by PHI in the development of time-lapse cytometry instrumentation and software.
Swiss-based Altium major investor BioStock

BioStock: PHI catches eye of major investor

BioStock contacted Altium’s CEO Goran Dubravcic to learn more about their incentives to invest in PHI.
Patrik Eschricht and Peter Egelberg shaking hands

BioStock: PHI comments on the new senior positions in the company

BioStock reached out to Patrik Eschricht and Peter Egelberg to better understand the background behind the recent management shift.
1…345678

Latest News

HoloMonitor M4FL and HoloMonitor M4 in one incubator

PHI announces significant order agreement from Altium for 20 HoloMonitor systems

PHI is excited to announce a significant order agreement from Altium for 20 HoloMonitor systems, which will be shipped in the second half of 2024.
HoloMonitor-incubator-zoom-banner

Interim Report 1 2024/25

The first quarter of 2024 has so far been a period of steady course and strategic positioning for Phase Holographic Imaging. Most notably, PHI has been very active around the globe in forming important academic and sales partnerships during this summer and preparing for future growth.

The exercise period for warrants of series TO 4 commences today

Today is the first day for the exercise of Phase Holographic Imaging PHI AB’s warrants of series TO 4 which were issued in connection with the preferential issue of units that the Company carried out during 2022. The period lasts until October 3, 2024.
See All News